Dr. Stephanie Pasas-Farmer
Dr. Pasas-Farmer focuses her efforts on helping small to large biotechnology and pharmaceutical research organizations transform early stage biological activities into potential new drug candidates with supporting bioanalysis and regulatory compliance planning.
Her bioanalytical consulting practice specializes in the areas of discovery and regulated bioanalysis for pharmaceutical, biologics and hybrid technologies, including antibody-drug conjugate technology. She brings extensive expertise in both quantitative and qualitative bioanalysis using LC-MS/MS.
Throughout her experience at biopharmaceutical companies and contract research organizations, Dr. Pasas-Farmer held roles overseeing scientific and business management functions and steadily took new responsibilities in operational leadership of regulated bioanalysis activities for both small and large molecules.
Dr. Pasas-Farmer earned her PhD and MSc degrees with honors in pharmaceutical chemistry from the University of Kansas. She received a BS degree in chemistry from St. Mary’s College of Notre Dame.
In addition to frequent contributions to peer-reviewed publications and industry conferences, she has been an active steering committee member of the Development and Discovery divisions of the national meeting Applied Pharmaceutical Analysis (APA).
Dr. Tony Chilton
Dr. Tony Chilton is a senior consultant and project lead at BioData Solutions.
Bringing more than 30 years of experience in drug discovery and clinical development, with expertise in translational development planning and oversight, bioanalytical laboratory operations, regulatory compliance, Dr. Chilton advises clients on bioanalysis program strategy.
Most recently he served as Senior Director at Roivant Sciences, where he led the company’s bioanalytical/biomarker activity to provide support of non-clinical and clinical projects across five therapeutic areas.
Dr. Chilton has held executive-level positions at pharmaceutical and contract research organizations, and was CEO of a publicly traded global CRO. In addition, he founded a management consultancy focused on assisting life science companies with strategic management to meet development milestones.
He earned a doctor of philosophy degree in analytical chemistry from the University of Hertfordshire, (United Kingdom) and received a bachelor of science degree with honors in chemistry from the University of East Anglia (United Kingdom).